Portal hypertensive enteropathy

Abstract

Portal hypertensive enteropathy (PHE) is a condition that describes the pathologic changes and mucosal abnormalities observed in the small intestine of patients with portal hypertension. This entity is being increasingly recognized and better understood over the past decade due to increased accessibility of the small intestine made possible by the introduction of video capsule endoscopy and deep enteroscopy. Though challenged by its diverse endoscopic appearance, multiple scoring systems have been proposed to classify the endoscopic presentation and grade its severity. Endoscopic findings can be broadly categorized into vascular and non-vascular lesions with many subtypes of both categories. Clinical manifestations of PHE can range from asymptomatic incidental findings to fatal gastrointestinal hemorrhage. Classic endoscopic findings in the setting of portal hypertension may lead to a prompt diagnosis. Occasionally histopathology and cross sectional imaging like computed tomography or magnetic resonance imaging may be helpful in establishing a diagnosis. Management of overt bleeding requires multidisciplinary approach involving hepatologists, endoscopists, surgeons, and interventional radiologists. Adequate resuscitation, reduction of portal pressure, and endoscopic therapeutic intervention remain the main principles of the initial treatment. This article reviews the existing evidence on PHE with emphasis on its classification, diagnosis, clinical manifestations, endoscopic appearance, pathological findings, and clinical management. A new schematic management of ectopic variceal bleed is also proposed.

Key Words: Portal hypertension; Enteropathy; Intestinal vasculopathy; Ectopic varices; Gastrointestinal bleeding

Core tip: Portal hypertensive enteropathy (PHE) is an under recognized complication of portal hypertension. It can present with a broad spectrum of clinical manifestations and endoscopic findings, making its diagnosis challenging. Video capsule endoscopy and deep enteroscopy are diagnostic tools of choice. PHE should be considered in patients with portal hypertension who present with occult or overt gastrointestinal bleeding, especially when portal hypertensive gastropathy and advanced cirrhosis are also present. Adequate resuscitation, reduction of portal pressure, and endoscopic therapeutic intervention remain the mainstay of initial treatment though definitive management may require a multidisciplinary approach involving hepatologists, endoscopists, surgeons, and interventional radiologists.

INTRODUCTION

Portal hypertension is defined as increased pressure in portal circulation, as estimated with the measurement of hepatic venous pressure gradient (HVPG)[1] which is the difference between wedge hepatic venous pressure (hepatic sinusoidal pressure) and free hepatic venous pressure. HVPG of more than 6 mmHg is considered abnormal[1,2]. Clinically significant portal hypertension occurs when HVPG is more than 10 mmHg and it is considered severe portal hypertension when HVPG is more than 12 mmHg[3,4]. Cirrhosis with consequent increased hepatic vascular resistance and portal venous inflow remains the most common etiology of portal hypertension, though it can also occasionally be seen due to other pre and post hepatic conditions such as congestive heart failure, Budd-Chiari syndrome, portal vein thrombosis, etc. The major clinical manifestations of portal hypertension were first recognized in the late nineteenth century and portal hypertension was described as a clinical syndrome of ascites, splenomegaly, and esophageal hemorrhage by Gilbert and Carnot in 1902[5]. Rupture and consequent hemorrhage from esophageal varices remains the most lethal complication of portal hypertension and therefore guidelines now call for periodic endoscopy for surveillance of these varices. Upper and lower endoscopy have led to recognition of other mucosal changes of gastrointestinal tract which previously had been less well recognized.

Microcirculatory changes of gastric mucosa, as a result of portal hypertension was first described as congestive gastropathy in 1985 by McCormack et al[6]. The characteristic findings of mosaic-pattern mucosa (irregular, cleft-bordered polygonal reticulated area, or snake skin-like pattern), small flat red-point lesions, elevated large cherry red spots, and black-brown spots have been variously termed as inflammatory gastritis, mucosal vasculopathy, portal hypertensive mucosa, and portal hypertensive gastropathy[6-10]. Subsequent studies suggested that these changes may be found in other areas of gastrointestinal tract as well[11-14]. The term, portal hypertensive colopathy, was used to describe similar abnormalities found in the colon of patients with portal hypertension. Endoscopic findings of portal hypertensive colopathy include diffuse erythematous and edematous mucosa, inflammatory (colitis-like) lesions, angiodysplasia-like lesions, and ectopic or anorectal varices[15-24].

Once the gastric and colonic mucosal changes associated with portal hypertension were recognized, jejunal and ileal mucosal changes were also noted. Occasional reports suggested small bowel bleeding in cirrhotic patients which was presumed to be a consequence of portal hypertension. The introduction of video capsule endoscopy and deep enteroscopy has increased our ability to evaluate the small bowel completely with good quality imaging and has led to better recognition and understanding of these portal hypertensive changes in the small bowel. This article reviews the existing evidence on portal hypertension-related changes in the small intestine, also known as portal hypertensive enteropathy (PHE) with emphasis on its classification, clinical manifestations, endoscopic appearance, and clinical management.

DEFINITION AND CLASSIFICATION

PHE previously termed portal hypertensive intestinal vasculopathy[25], includes pathologic changes and mucosal abnormalities observed in the small intestine of patients with portal hypertension[26]. Like other portal hypertensive related changes, PHE has also been reported in non-cirrhotic etiologies of portal hypertension[27]. The definition and diagnosis of PHE have evolved over the past decade due to increased accessibility of the small intestine. Introduction of video capsule endoscopy (VCE) and deep enteroscopy has shed more light into this area of the gastrointestinal tract and redefined the disease. Multiple scoring systems have been proposed to classify PHE and to grade its severity[28-30].

De Palma et al[29] were among the first groups to study small intestinal changes in cirrhotic patients with portal hypertension using VCE[29]. They found that portal hypertensive gastropathy and portal hypertensive colopathy are significantly associated with PHE and suggested these changes across different parts of the gastrointestinal tract could be the regional manifestations of the same process in portal hypertension, rather than distinct entities. Other parameters that were associated with PHE in their study were grade 2+ or larger esophageal varices and Child-Pugh class C cirrhosis. They classified endoscopic findings of PHE into two categories: mucosal inflammatory-like abnormalities (edema, erythema, granularity, friability) and vascular lesions (cherry red spots, telangiectasias, or angiodysplasia-like lesions, varices)[29].

Abdelaal et al[28] classified PHE lesions into 4 subtypes: inflammatory-like lesions, red spots, angioectasia, and small bowel varices. They created a scoring system based on VCE findings, giving each type one point with an additional point for multiple (more than two) lesions. Using this PHE score, they confirmed the findings by De Palma et al[29] by redemonstrating the association between PHE and portal hypertensive gastropathy, large esophageal varices, Child-Pugh class C cirrhosis, and a history of prior endoscopic variceal injection sclerotherapy or banding ligation in a non-randomized, case-controlled, prospective study[28].

Kodama et al[30] proposed a PHE scoring system based on double balloon enteroscopy findings. They classified PHE lesions into 2 categories: villous abnormalities and vascular lesions. They further subclassified each category into 3 subtypes: edema, atrophy and reddening for villous abnormalities, and angiodysplasia-like lesions, dilated/proliferated vessels, and varices for vascular lesions. A single point is given for each type, resulting in a scoring system with a maximum of 6 points. This scoring system, however, was associated with only the presence of ascites, making its clinical significance unclear[30].

In summary, PHE lesions can be described based on VCE findings or optical endoscopic findings. They can be categorized into subtypes of vascular and non-vascular lesions. Despite multiple proposed scoring systems as described in Table 1, presently there is insufficient data to standardize or validate these systems. Besides ectopic varices and bleeding lesions, the clinical significance of other subtypes of mucosal changes remains unclear.

Table 1 Endoscopy based classification systems for portal hypertensive enteropathy.

	De Palma et al[29]	Abdelaal et al[28]	Kodama et al[30]
Classification	Inflammatory lesions	Inflammatory-like lesions	Villous abnormalities
	Vascular lesions	Red spots	Edema
		Angioectasia	Atrophy
		Small bowel varices	Erythema
			Vascular lesions
			angiodysplasia-like lesions
			dilated/proliferated vessels
			varices
Scoring system	None	One point for each type of lesion. An additional point for > 2 lesions	One point for each type of lesion
Clinical significance	Associated with PHG, PHC, large esophageal varices and Child-Pugh class C cirrhosis	Associated with PHG, large esophageal varices, Child-Pugh class C cirrhosis, and a history of EVL	Associated with ascites

PHG: Portal hypertensive gastropathy; PHC: Portal hypertensive colopathy; EVL: Endoscopic variceal ligation.

EPIDEMIOLOGY

There is great heterogeneity among reported prevalence of PHE ranging from 15% up to 82% in cirrhotic patients[5,27,29,31]. We believe that this heterogeneity is a result of a wide spectrum of clinical severity of portal hypertension in cirrhotic patients, together with increase in reported prevalence due to recent advances in small bowel imaging in the past decade. The prevalence of PHE ranges only 15%-25% in studies where traditional endoscopic modalities like duodenoscopy, push enteroscopy or colonoscopy with ileal intubation were used[14,20] but is much higher (40%-82%) in other studies when VCE was used[5,26,29,32-35].

Prevalence of each type of endoscopic finding also varies among studies. Red spots (22.2%-62.2%) and angiodysplasia-like lesions (24.3%-55.7%) seem to be more common than inflammatory-like lesions (5.6%-13%) or varices (8.1%-38.9%). Mixed lesions, especially multiple vascular lesions (varice, angiodysplasia-like, and red spots) can be seen in up to 22.3%[26,29,36]. Small bowel varices account for 12%-35% of all ectopic varices[37,38]. Portal hypertensive polypoid enteropathy is a rarer manifestation of PHE and polypoid lesions are less common in the small intestine (0.3%) compared to polypoid gastropathy (0.6%)[39].

Actively bleeding lesions are not uncommon and can be seen in up to 17.8% of all patients with PHE, suggesting their clinical significance as a possible culprit source of obscure overt or obscure occult gastrointestinal bleeding. The bleeding lesions are commonly from angiodysplasia-like lesions and varices, though occasionally can be associated with polypoid enteropathy as well[26,29].

CLINICAL PRESENTATION

PHE should be suspected when there is gastrointestinal bleeding or anemia not otherwise explained by more common etiologies, along with signs of portal hypertension such as ascites, splenomegaly, thrombocytopenia, or hepatic venous pressure gradient more than 8 mmHg[39,40]. PHE can present as anemia, melena, hematochezia, hematemesis or may be asymptomatic. Fatal and life threatening ectopic variceal hemorrhage in small intestine has also been reported[26,38-41]. Small intestinal variceal rupture can present with a classic triad of hematochezia (without hematemesis), portal hypertension, and previous intra-abdominal surgery[38,42,43]. The most common indication for diagnostic work up is occult gastrointestinal bleeding.

Certain clinical parameters have been shown to associate with PHE and can serve as clues to search for the disease. These parameters include large esophageal varices, history of endoscopic variceal injection sclerotherapy, history of endoscopic variceal ligation, portal hypertensive colopathy, portal hypertensive gastropathy, low hemoglobin, thrombocytopenia, splenomegaly, multiple signs of portal hypertension seen on CT scan, and Child-Pugh class C[26,28,29,36,44,45]. However, not all of these associations were seen in every study. Only advanced cirrhosis (Child-Pugh class C) and the presence of portal hypertensive gastropathy were consistently associated with PHE in most studies[28,29,36,44]. PHE has also been reported in non-cirrhotic etiologies of portal hypertension like polycystic liver disease, portal vein thrombosis, and Budd-Chiari syndrome[27,46-48]. PHE is usually diagnosed by a VCE or a deep enteroscopy[35].

ENDOSCOPIC FINDINGS

Endoscopically, PHE can be associated with a wide range of mucosal changes including the mucosal edema, congested rounded blunt villi giving a classic “herring-roe” appearance, loss of vascularization, friability, hyperrhemia, flat red spots, angiodysplasia-like lesions, pigmented black-brown spots, mucosal granularity, ulcers, reticulated mosaic-like pattern mucosa, protruding red bumps, inflammatory polyps, and varices[11,26,39,44,47,49,50]. Recognizing these findings through an optical endoscope or capsule endoscopy can lead to a prompt diagnosis and avoid further unnecessary and potentially harmful intervention. As mentioned above, these endoscopic findings can be classified into vascular and non-vascular lesions. They can be further categorized as inflammatory-like lesions, red spots, angioectasia, and small bowel varices[28]. Special attention should be paid to vascular lesions such as red spots, angioectasia-like lesions, and varices, which are more likely to cause clinically significant bleeding and are amenable to endoscopic intervention[28].

Red spots are small, symmetrical, uniformly erythematous, vascular areas on intestinal mucosa as shown in Figure 1. The lesions are usually flat. They are a very common manifestation of PHE and have been reported in up to 55% of cirrhotic patients with portal hypertension in one series[28].

Figure 1 Mucosal red spots.

Angioectasia are aberrant submucosal vascular lesions, characterized as small red patches with arborizing ectatic vessels as shown in Figure 2. Variceal lesions in the small bowel are described as tortuously enlarged veins that usually have serpiginous or nodular shape with overlying mosaic-like shining mucosa with bluish discoloration as shown in Figure 3A and B[26,27]. Endoscopic characters of these lesions should be promptly recognized to avoid potentially disastrous diagnostic biopsy attempts.

Figure 2 Angiodysplasia-like lesion.

Figure 3 Ileal varices (A and B).

Duodenal varices are most commonly found in the duodenal bulb and the second portion of duodenum[51-53]. Jejunal and ileal varices are more commonly seen in patients with history of abdominal surgery due to post surgical portosystemic collaterals related to bowel anastomosis and are more difficult to diagnose due to their deep location in the intestinal tract[38,42,43]. Small intestinal varices usually originate from portal venous trunk or superior mesenteric vein[48,54,55]. Polypoid enteropathy is a rare manifestation of PHE and can present in any part of the small intestine. Polypoid lesions can have varied endoscopic manifestations. They can be single or multiple, sessile or pedunculated, small or large and may occasionally mimic adenomatous polyps as shown in Figure 4A and B. They usually arise in the background of inflamed mucosa with classic mosaic or herring-roe pattern and have been associated with occult or overt gastrointestinal bleeding[39,49,50,56].

Figure 4 Portal hypertensive polypoid enteropathy (A and B).

Other inflammatory lesions include mucosal edema, granularity, patchy erythematous mucosa, and herring roe appearance (rounded blunted villi on the background of congested mucosa with granularity) as shown in Figures 5 and 6. Clinical significance of these lesions is unclear but it is believed that they are less likely to cause overt gastrointestinal bleeding[26,28,44].

Figure 5 Herring roe appearance of small bowel mucosa (A and B).

Figure 6 Mucosal edema with granularity of the small bowel (A and B).

Some of these endoscopic findings are non-specific and can pose a diagnostic dilemma especially in a patient whose portal hypertensive status is unknown. Differential diagnosis includes inflammatory bowel disease, celiac disease, arteriovenous malformations, and familial adenomatous polyposis. Biopsy of non-vascular lesions can be performed with caution to confirm the diagnosis.

In portal hypertension when splanchnic blood flow cannot effectively return to the systemic circulation, consequently splanchnic vasodilation ensues and mucosa of small intestine becomes congested. Therefore, histopathologic changes of PHE show evidence of congested mucosa and vascular ectasia. These histologic findings include capillary dilation in the lamina propria (mean vascular diameter of 380 micrometers), increased capillary wall thickness, fibromuscular proliferation, a decreased villous/crypt ratio, neovascularization, vascular ectasia, vessels containing fibrin thrombi, inflammatory lymphoplasmatocytic cells infiltration in the lamina propria, reactional nucleocytoplasmic atypia in the epithelial cells, and crenulated aspect of the glands[13,14,39,57-59]. However, these histopathological changes are non-specific and can be seen in patients without portal hypertension and in patients with normal endoscopic findings[12-14]. Therefore, the diagnosis of PHE should not be made on histopathology alone, but rather in conjunction with other clinical and endoscopic characteristics.

OTHER DIAGNOSTIC TESTS

Jeon et al[26] has evaluated the use of computerized tomography (CT) scan findings of portal hypertension such as esophageal varices, gastric varices, peri umbilical varices, portal hypertensive colopathy, portal hypertensive gastropathy, portal hypertensive cholecystopathy, splenomegaly, and ascites as the radiologic predictors of PHE. They have created a scoring system giving each CT finding one point with a maximum score of 6 points. A CT score of more than 3 was found to be significantly associated with PHE[26]. Cross sectional imaging by computed tomography angiography and magnetic resonance angiography can also aid in evaluation of vascular origin of the ectopic varices[55,60].

Abdelaal et al[28] have explored the use of a transient elastrography (FibroScan^®), a novel non-invasive ultrasound-based technology using pulse-echo ultrasound signals to measure liver stiffness as a surrogate marker of severity of portal hypertension in cirrhotic patients[4,61]. They found that a high transient elastography score had a linear relation with a high PHE score (r² = 0.314, P-value 0.004), suggesting that higher severity of PHE may be associated with higher degree of liver disease and portal hypertension. Mean liver stiffness measurement in PHE group was 29 kPa, which is much higher than the portal hypertensive cut-off value of 13.6 kPa[4,28]. They concluded that transient elastography may be a new non-invasive method for detecting the presence and severity of PHE in cirrhotic patients[28].

MANAGEMENT

VCE is the preferred initial diagnostic modality in evaluating the small bowel due to its non-invasive nature[5,27,33,35]. It also serves as a road map for subsequent interventions. A deep enteroscopy is warranted when a therapeutically amenable lesion is found on VCE in patients with obscure gastrointestinal bleeding[27]. Different endoscopic findings may require different therapeutic interventions.

Due to its rarity and insufficient evidence, there are no standardized therapeutic guidelines for symptomatic PHE[40]. Clinical significance and the need for any intervention for inflammatory lesions and red spots remain unclear. Argon plasma coagulation is generally used for angioectasia[27] while multiple approaches have been used for small bowel varices and polypoid enteropathy[39,55,56,62,63].

Treatment of portal hypertensive polypoid enteropathy depends on number of polyps and endoscopic accessibility. A polypectomy can be safely performed if the polyp is accessible and amenable for endoscopic removal. Endoclip can be used at the stalk to achieve complete hemostasis[56]. Argon plasma coagulation can be used on the inflamed surface of bleeding polyp to achieve hemostasis but recurrent bleeding has been reported[39]. Non-selective beta blocker, transjugular intrahepatic portosystemic shunt (TIPS), surgical small bowel resection, and liver transplantation have all been reported anecdotally to be successful treatment for portal hypertensive polypoid enteropathy[39,56].

Bleeding small bowel varices occurs in 0.4% of patients with portal hypertension and account for up to 5% of all variceal bleeding. Similar to esophagogastric variceal hemorrhage, it usually presents as massive life-threatening hemorrhage with mortality rate as high as 40%[38,40,51,54]. Available therapeutic options are endoscopic treatment, surgical interventions, and interventional radiological approaches. Similar to polypoidal lesions, management of small bowel varices depends largely on endoscopic accessibility, patient’s surgical risk, available therapy and local expertise.

Adequate resuscitation with intravenous fluids, blood product transfusion, close monitoring, and airway protection remain the main principles of initial management. The benefit of medical management has not been extensively studied in ectopic varices or other manifestations of PHE, but given its established role in esophageal and gastric variceal management[64], it is reasonable to consider the use of vasoactive agents such as octreotide and non-selective beta blockers to reduce the splanchnic and portal pressure in both primary and secondary prophylaxis of ectopic varices[40].

Despite the technical challenges, endoscopic band ligation and endoscopic variceal obturation with tissue glue monomer such as N-butyl-2-cyanoacrylate are endoscopic interventions of choice for hemostasis in ectopic variceal rupture. However, the achieved hemostasis is temporary and re-bleeding is a major concern[52,53]. Endoscopic variceal obturation has shown better success and lower re-bleeding rate compared to endoscopic variceal banding[38,65-68]. Endoscopic sclerotherapy and band ligation are not recommended for large varices, especially the varices with larger diameter than the endoscope itself. This is because incomplete banding can lead to mucosal defect in the remaining varix causing recurrent hemorrhage while excessive dilution of injected sclerosant in large varices decreases the success rate of the sclerotherapy[40,63]. Limited evidence suggests supplemental use of argon plasma coagulation after variceal band ligation as a successful intervention in prevention of rebleeding in esophageal and ileal varices and can be considered in endoscopic management of ectopic varices as well[69-71].

Interventional radiology approaches are effective modalities especially for large varices, lesions that are not endoscopically accessible, and for patients with poor overall general condition who are poor surgical candidates[38,63,72]. These interventions include TIPS, balloon-occluded retrograde transvenous obliteration (B-RTO), and percutaneous coil embolization[38,40,55,62].

Even though TIPS is relatively safe procedure, widely available, and with good success rate, it has limitations in patients with hepatic encephalopathy, high MELD score, severely decompensated cirrhosis, and severe hepatic atrophy[73,74]. It, however, remains an effective intervention to control the variceal bleeding and prevent recurrence, especially in those who have failed endoscopic and medical management. The American Association for the Study of Liver Diseases (AASLD) has recommended TIPS as the preferred approach for the prevention of rebleeding of ectopic varices (including intestinal, stomal, and anorectal varices)[75].

Percutaneous transhepatic and transjugular coil embolization are other radiological interventions that may offer a focal occlusion of the feeding vein of the varices. They can be safely performed even in a large varix, and have good short term results. However, as the portal system is not decompressed, they carry a very high recurrent bleeding rate[76-81]. A retrospective study by Macedo et al[76] showed that even though an immediate bleeding control can be achieved in 75% of patients receiving coil embolization, the rebleeding rate was 67% with a mean bleeding-free interval of 7.8 mo. This result was similar to previous studies that demonstrated a rebleeding rate as high as 55% at 6 mo and 92% at 4 years[76,82]. A combined approach of TIPS and percutaneous embolization in the setting of persistent bleeding after TIPS is preferred[76].

B-RTO is a non-surgical therapy that can occlude not only the varices, but also the feeding afferent and efferent vessel. It is particularly useful in patients who bleed at lower portal pressure, have non-patent portal vein, or are not candidates for TIPS. The success of B-RTO in treating small bowel ectopic varices has been reported, especially in the Japanese literature[83-86]. However, B-RTO can cause significant elevation of porto-systemic pressure gradient and subsequent variceal formation has also been reported[55,87].

Surgical approaches, such as portosystemic surgical shunt, segmental small bowel resection and surgical variceal ligation, can be performed but are usually reserved for patients who are refractory to other therapy[38,41,88,89]. Surgical shunt such as distal splenorenal shunt has equal efficacy as TIPS with no difference in survival or hepatic encephalopathy rate but is less cost-effective approach compared to TIPS[75]. Other surgical approaches such as duodenotomy with simple oversewing of the varix and duodenal dearterialization with stapling have been reported[90,91].

Similar to what Helmy et al[40] have proposed, management of bleeding ectopic varices should focus on adequate initial resuscitation and use a multimodality approach depending on availability and local expertise of each institution. We suggest an algorithm for management of bleeding ectopic varices in Figure 7. As mentioned above, we also recommend individually tailored therapies for non variceal bleeding depending on the clinical situation and local expertise.

Figure 7 Management of bleeding ectopic varices. TIPS: Transjugular intrahepatic portosystemic shunt; APC: Argon plasma coagulation; BRTO: Balloon-occluded retrograde transvenous obliteration.

CONCLUSION

PHE-associated small bowel mucosal changes are increasingly being recognized due to introduction of VCE and deep enteroscopy of VCE and deep enteroscopy which enables a more thorough small bowel evaluation than previously possible. Endoscopically, PHE can have myriad presentations ranging from mild mucosal inflammatory changes to angioectasias, inflammatory appearing polyps, and occasionally as large ectopic varices. Due to the non-specific endoscopic and histopathological findings, a high index of suspicion is required to recognize and accurately diagnose this condition. VCE and/or a deep enteroscopy are the current preferred modalities for establishing the diagnosis. PHE has been known to cause significant life-threatening overt gastrointestinal bleeding or be a source of occult gastrointestinal blood loss. However, due to low prevalence and lack of large studies, its prognostic value and clinical significance on morbidity and mortality remain unclear. Management of PHE has not yet been standardized and should be individualized based on acuity and severity of the hemorrhage, endoscopic accessibility of the lesion, surgical risk of the patient, patency of portal vein, available therapy and expertise of each institution.

ACKNOWLEDGMENTS

The authors would like to acknowledge Yue Xue MD, Department of Pathology, Emory School of Medicine for providing the picture of histopathological changes in PHE (Figure 8).

Figure 8 Histopathological changes of portal hypertensive enteropathy (A-D).